- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03599752
Chemotherapy and/or Metastasectomy in Treating Patients With Metastatic Colorectal Adenocarcinoma With Lung Metastases
The Role of Multimodality Management in Risk-Stratified Patients With Lung-Limited Metastatic Colorectal Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. To compare recurrence-free survival in patients with "low risk" lung-limited metastatic colorectal cancer (mCRC) undergoing pulmonary metastasectomy with or without perioperative chemotherapy.
II. To compare overall survival in patients with "high risk" lung-limited mCRC receiving systemic chemotherapy with or without surgical resection.
SECONDARY OBJECTIVES:
I. To compare grade 3 and 4 adverse events in patients receiving surgical resection and/or chemotherapy in the management of lung-limited mCRC.
EXPLORATORY OBJECTIVES:
I. To evaluate for changes in circulating tumor deoxyribonucleic acid (DNA) following surgical resection and/or systemic chemotherapy in patients with lung-limited mCRC.
OUTLINE: Patients are assigned to 1 of 2 risk groups (low or high).
GROUP 1 (LOW RISK): Patients are randomized to 1 of 2 groups.
GROUP 1A: Patients receive standard of care chemotherapy for 3 months prior to and 3 months after undergoing metastasectomy in the absence of disease progression or unacceptable toxicity.
GROUP 1B: Patients undergo metastasectomy.
GROUP 2 (HIGH RISK): All high risk patients receive standard of care chemotherapy for 3 months in the absence of disease progression or unacceptable toxicity. Patients without progressive disease after 3 months are then randomized to 1 of 2 groups.
GROUP 2A: Patients undergo metastasectomy.
GROUP 2B: Patients continue standard of care chemotherapy for 6 months in the absence of disease progression or unacceptable toxicity. Patients with stable disease or radiographic response after 6 months may then cross over to Group 2A.
After completion of study treatment, patients are followed up periodically for up to 5 years.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Mara B. Antonoff, MD
- Phone Number: 713-563-3100
- Email: mbantonoff@mdanderson.org
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2M9
- University Health Network Princess Margaret Cancer Center P2C
-
-
Quebec
-
Montreal, Quebec, Canada, H3T 1J7
- University of Montreal
-
-
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washington University School of Medicine
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19107
- Thomas Jefferson University
-
-
Texas
-
Houston, Texas, United States, 77030
- M D Anderson Cancer Center
-
Houston, Texas, United States, 77030
- Baylor Colllege of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Histological confirmation of colorectal adenocarcinoma
- Metastatic colorectal cancer involving the lung classified as determined by the treating clinical team
- Diagnosis of colorectal metastasis to lung made either histologically with trans-thoracic needle biopsy or clinically based on radiographic imaging
Identification as a medically appropriate candidate for surgical resection of the lung metastasis (metastases) according to the evaluating cardiothoracic surgeon. Standard justification for deeming a patient medically operable based on:
Pulmonary reserve adequate to tolerate complete resection of all intrathoracic disease, as deemed by thoracic surgeon, which may be determined by:
- Baseline forced expiratory volume in one second (FEV1) > 40% predicted
- Post-operative predicted FEV1 > 30% predicted
- Diffusion capacity of the lung for carbon monoxide (DLCO) > 40% predicted
- Absent baseline hypoxemia and/or hypercapnia
- Exercise oxygen consumption > 50% predicted
- Absent severe pulmonary hypertension
- Absent severe cerebral, cardiac, or peripheral vascular disease
- Absent severe chronic heart disease
- Ability to tolerate surgical resection and acceptable operative risk as deemed by thoracic surgeon based on performance status and medical comorbidities
- Identification as a medically appropriate candidate for systemic chemotherapy at the discretion of the evaluating medical oncologist
- Resection/definitive therapy of primary colorectal tumor with no suspicion of recurrence. Prior radiation to a rectal adenocarcinoma is permitted
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Ability to provide informed consent for participation
- Leukocytes >= 2,000/mcL
- Absolute neutrophil count >= 1,000/mcL
- Hemoglobin >= 9.0 gm/dL
- Platelet count >= 100,000/mcL
- Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (except patients with Gilbert Syndrome, who can have total bilirubin < 3.0 mg/dL)
- Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x ULN
- Serum creatinine =< 1.5 x ULN OR creatinine clearance (CrCl >= 50 mL/min (if using the Cockcroft-Gault formula)
- Patients (men and women) of child bearing potential should use an effective (for them) method of birth control throughout their participation in this study
Exclusion Criteria:
- Tumor involvement at other metastatic sites (e.g., liver, distant lymph nodes) that has not been definitively treated. Prior surgical resection for metastatic disease at other (non-pulmonary) sites is permitted
- Presence of intact primary colorectal adenocarcinoma (or of an anastomotic recurrence)
- Previous radiotherapy to a lung metastasis that is still detectable radiographically
- Known dihydropyrimidine dehydrogenase (DPD) deficiency that would preclude the patient from tolerating 5- fluorouracil chemotherapy
- Prior intolerance of systemic therapies used as standard regimens in the treatment of metastatic CRC that would prohibit further receipt of systemic chemotherapy and/or biologic agents -e.g.,5-fluorouracil, oxaliplatin, irinotecan, anti-VEGF therapies (e.g., bevacizumab, ramucirumab), or anti-EGFR therapies (e.g., cetuximab, panitumumab, for patients with RAS wild-type colorectal tumors)
- Prior therapy with regorafenib or trifluridine/tipiracil (TAS-102) for metastatic/unresectable colorectal cancer
- Synchronous primary or prior malignancy in the past 5 years other than non-melanomatous skin cancer or in situ cancer
- Pregnant or lactating women, as treatment involves unforeseeable risks to the embryo or fetus
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group 1A (chemotherapy, metastasectomy)
Low risk patients receive standard of care chemotherapy for 3 months prior to and 3 months after undergoing metastasectomy in the absence of disease progression or unacceptable toxicity.
|
Receive chemotherapy
Other Names:
Undergo pulmonary metastasectomy
|
Experimental: Group 1B (metastasectomy)
Low risk patients undergo metastasectomy.
|
Undergo pulmonary metastasectomy
|
Experimental: Group 2A (metastasectomy)
High risk patients undergo metastasectomy.
|
Undergo pulmonary metastasectomy
|
Experimental: Group 2B (chemotherapy)
High risk patients continue standard of care chemotherapy for 6 months in the absence of disease progression or unacceptable toxicity.
Patients with stable disease or radiographic response after 6 months may then cross over to Group 2A.
|
Receive chemotherapy
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Recurrence-free survival (Low risk)
Time Frame: Up to 2 years
|
The primary objective for the low risk group is to evaluate the efficacy of chemotherapy plus surgical resection versus surgical resection alone measured by recurrence-free survival (RFS).
The event includes recurrence and death due to any cause.
Patients will be stratified at randomization according to three variables: age (age >= 60 years vs age < 60 years), RAS mutation status (mutant vs wild type), and location of primary tumor within colon/rectum (right/cecum/ascending colon/hepatic flexure/transverse colon vs left/distal to transverse colon).
|
Up to 2 years
|
Overall survival (High risk)
Time Frame: Up to 2 years
|
The primary objective for the high-risk group is to evaluate the efficacy of chemotherapy plus surgical resection versus chemotherapy alone measured by overall survival (OS).
The event includes death due to any cause.
Patients will be stratified at randomization according to 4 variables: response to chemotherapy in the preceding three months of treatment (complete or partial response vs stable disease by Response Evaluation Criteria in Solid Tumors [RECIST] 1.1 criteria), RAS mutated vs RAS wild type tumors, right versus left-sided primary tumors, and oxaliplatin-based vs irinotecan-based chemotherapy in the initial treatment period on study.
|
Up to 2 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Mara B. Antonoff, MD, M.D. Anderson Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Colonic Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Colorectal Neoplasms
- Adenocarcinoma
Other Study ID Numbers
- 2017-0905 (Other Identifier: M D Anderson Cancer Center)
- NCI-2018-01456 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Colorectal Adenocarcinoma
-
Imperial College LondonNational Institute for Health Research, United Kingdom; Imperial Health Charity and other collaboratorsActive, not recruitingColorectal Cancer | Colorectal Polyps | Colorectal AdenocarcinomaUnited Kingdom
-
University of ChicagoVerastem, Inc.RecruitingColorectal Cancer | Colorectal Cancer Metastatic | Colorectal Adenocarcinoma | Advanced Colorectal Carcinoma | Advanced Colorectal AdenocarcinomaUnited States
-
Mayo ClinicCompletedMetastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Rectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Metastatic... and other conditionsUnited States
-
Zhejiang Cancer HospitalNot yet recruitingMetastatic Colorectal Cancer | Metastatic Colorectal Adenocarcinoma | CRCChina
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingProgressive Disease | Recurrent Colorectal Carcinoma | Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingMetastatic Colorectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Metastatic Small Intestinal Adenocarcinoma | Stage IV Small Intestinal Adenocarcinoma AJCC v8United States
-
National Cancer Institute (NCI)RecruitingMetastatic Colorectal Adenocarcinoma | Refractory Colorectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8United States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingMetastatic Colorectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Metastatic Microsatellite Stable Colorectal Carcinoma | Advanced Microsatellite Stable Colorectal Carcinoma | Advanced Colorectal AdenocarcinomaUnited States
-
City of Hope Medical CenterRecruitingColorectal Neoplasms | Colorectal Cancer | Colorectal Disorders | Colorectal Adenocarcinoma | Colorectal Cancer Stage II | Colorectal Cancer Stage III | Colorectal Cancer Stage IV | Colorectal Polyp | Colorectal Neoplasms Malignant | Colorectal Adenomatous Polyp | Colorectal Cancer Stage I | Colorectal Adenoma... and other conditionsUnited States, Italy, China, Spain, Japan
-
Roswell Park Cancer InstitutePfizerRecruitingAdvanced Malignant Solid Neoplasm | Metastatic Colorectal Adenocarcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Clinical Stage III... and other conditionsUnited States
Clinical Trials on Chemotherapy
-
University of WashingtonNational Cancer Institute (NCI)CompletedAdult Acute Myeloid Leukemia | Adult Myelodysplastic SyndromeUnited States
-
Cancer Institute and Hospital, Chinese Academy...Unknown
-
International Atomic Energy AgencyCompletedNon Small Cell Lung CancerChile, China, Croatia, Egypt, India, Malaysia, Malta, Morocco, Pakistan, Panama, Peru, South Africa, Tunisia
-
Ping LiangNot yet recruitingChemotherapy | Liver Metastases | Colorectal Carcinoma
-
Second Affiliated Hospital, School of Medicine,...UnknownUnresectable Gastric Cancer | Successful Conversion Rate of OperationChina
-
Jiangsu HengRui Medicine Co., Ltd.Completed
-
Yantai Yuhuangding HospitalRecruiting
-
Shenzhen SiBiono GeneTech Co.,LtdUnknown
-
Ruijin HospitalNot yet recruitingGastric Cancer | Neoadjuvant ChemotherapyChina
-
Second Affiliated Hospital, School of Medicine,...Hebei Medical University Fourth Hospital; Zhejiang University; Cancer Hospital...Not yet recruitingUnresectable Metastatic Colorectal Cancer